Literature DB >> 429526

In vivo metabolism of progestins. V. The effect of protocol design on the estimated metabolic clearance rate and volume of distribution of medroxyprogesterone acetate in women.

C Gupta, J Osterman, R Santen, C W Bardin.   

Abstract

The metabolism of the synthetic progestin, [3H]medroxyprogesterone acetate (MPA), was studied in women using a single injection technique. Computer-implemented analysis was used to calculate the MCR (MCRMPA) and volume of distribution (VoMPA) from the steroid disappearance curve. The value of an objective curve-fitting technique was demonstrated. The effect of protocol design (number and frequency of samples) on these metabolic parameters was evaluated. The estimation of VoMPA was most sensitive to alterations of experimental design and biological variability, while MCR was less easily effected. The MCRMPA of 1668 +/- 146 (SEM) liters/day was lower than that for progesterone but higher than that of another synthetic steroid, dexamethasone. Treatment of women with MPA or aminoglutethimide, two drugs known to increase the rates of testosterone and dexamethasone metabolism, respectively, did not alter MCRMPA. From these observations we conclude 1) with the single injection technique it is difficult to estimate Vo of compounds such as MPA which are rapidly metabolized and 2) the MCRMPA was higher than expected and less susceptible to drug-induced changes than the clearance of other steroids.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 429526     DOI: 10.1210/jcem-48-5-816

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 2.  Clinical significance of differences in bioavailability of medroxyprogesterone acetate preparations.

Authors:  A D Stockdale; A Y Rostom
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

3.  Single-dose and steady-state pharmacokinetics of aminoglutethimide.

Authors:  P E Lønning; J S Schanche; S Kvinnsland; P M Ueland
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

4.  Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.

Authors:  S Lundgren; P E Lønning; A Aakvaag; S Kvinnsland
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 5.  Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.

Authors:  P E Lønning; S Kvinnsland
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 6.  Management of epilepsy in women.

Authors:  M D O'Brien; S K Gilmour-White
Journal:  Postgrad Med J       Date:  2005-05       Impact factor: 2.401

Review 7.  Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.

Authors:  E Samojlik; J D Veldhuis; S A Wells; R J Santen
Journal:  J Clin Invest       Date:  1980-03       Impact factor: 14.808

8.  Effect of medroxyprogesterone acetate on serum levels of LH, FSH, cortisol, and estrone in patients with endometrial carcinoma.

Authors:  E Vesterinen; N E Backas; K Pesonen; U H Stenman; T Laatikainen
Journal:  Arch Gynecol       Date:  1981
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.